Live price temporarily unavailable.
Contineum Therapeutics (CTNM) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Revenue | $50.0M | $0 | — |
| Growth (year over year) | — | −100.0% | — |
| Operating income | $16.1M | −$50.9M | −$68.1M |
| Operating margin | 32.2% | — | — |
| Net income | $22.7M | −$42.3M | −$60.0M |
| Net margin | 45.4% | — | — |
| EPS (diluted) | $0.08 | −$2.18 | −$2.17 |
| Balance sheet | |||
| Cash and equivalents | $15.5M | $21.9M | $75.6M |
| Total assets | $130.4M | $212.8M | $276.6M |
| Total liabilities | $5.70M | $14.8M | $15.7M |
| Shareholders' equity | −$67.9M | $198.1M | $261.0M |
| Cash flow | |||
| Operating cash flow | $19.3M | −$32.8M | −$55.3M |
| Capital expenditure | $414.0K | $514.0K | $231.0K |
| Free cash flow | $18.9M | −$33.4M | −$55.5M |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | — | — | — | — | — | — |
| Operating income | −$13.0M | — | −$18.1M | −$17.9M | −$14.9M | −$17.1M | −$16.9M | −$17.4M |
| Net income | −$10.3M | — | −$16.0M | −$16.0M | −$12.8M | −$15.2M | −$14.5M | −$15.2M |
| EPS (diluted) | −$0.40 | — | −$0.62 | −$0.62 | — | — | −$0.39 | −$0.40 |
| Balance sheet | ||||||||
| Cash and equivalents | $40.9M | $21.9M | $22.5M | $20.8M | $42.6M | $75.6M | $20.2M | $14.7M |
| Total assets | $216.0M | $212.8M | $198.3M | $182.9M | $190.8M | $276.6M | $261.3M | $250.4M |
| Total liabilities | $5.81M | $14.8M | $13.5M | $11.5M | $10.4M | $15.7M | $11.3M | $10.7M |
| Shareholders' equity | $210.2M | $198.1M | $184.8M | $171.4M | $180.5M | $261.0M | $250.0M | $239.7M |
| Cash flow | ||||||||
| Operating cash flow | −$6.17M | — | −$14.4M | −$15.7M | −$12.2M | −$13.0M | −$16.3M | −$11.5M |
| Capital expenditure | $82.0K | — | $47.0K | $44.0K | $98.0K | $42.0K | $312.0K | $6.00K |
| Free cash flow | −$6.25M | — | −$14.5M | −$15.7M | −$12.3M | −$13.1M | −$16.6M | −$11.5M |
From Contineum Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Contineum Therapeutics in our feed yet.